-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] R&D expenses, as an important part of investors' consideration of the company's development potential, have attracted much attention
.
In recent years, with the country's continuous emphasis on innovative drugs, pharmaceutical companies have begun to increase investment in research and development to achieve transformation
.
Among them, the old brand Yunnan Baiyao has also begun to firmly transform itself in the throes.
The data shows that in 2021, the R&D expenses of Yunnan Baiyao will increase by 82.
99% year-on-year, and 7 national scientific research platforms have been established
.
Yunnan Baiyao said that the competition of modern biomedical technology enterprises is essentially the competition of talents and innovation ability
.
In the future, Yunnan Baiyao will be based on an excellent talent team, driven by continuous innovation investment, and rely on strong independent research and development capabilities and global resource integration capabilities to integrate various product forms to create comprehensive pharmaceutical solutions
.
It is also worth noting that as of the close of April 8, 1,220 of the 2021 annual results disclosed by 1,369 A-share listed companies disclosed research and development expenses, totaling 519.
893 billion yuan, a year-on-year increase of 20.
26%
.
Among them, according to the sorting out, most of the companies with R&D expenses accounting for a large proportion of operating income belong to the technological innovation industry, involving fields such as computers, medicine and biology
.
For example, in terms of the proportion of R&D expenses, three pharmaceutical companies, including Dizhe Pharmaceuticals, Shouyao Holding, and Shanghai Yizhong, will account for more than 320% of their operating income in 2021
.
In addition, the R&D expenditures of 36 companies including Junshi Bio, Rongchang Bio, Sunshine Guojian, and Microchip Bio also accounted for more than 20% of their operating income
.
Among them, Junshi Bio’s R&D investment in 2021 will increase by 15.
07% year-on-year to 2.
069 billion yuan, accounting for more than 50% of the total revenue; the number of R&D personnel has increased from 667 to 896, of which R&D personnel with doctoral and master’s degrees have reached 420 people
.
It is understood that in recent years, many pharmaceutical companies have continuously expanded their R&D investment to promote the development of innovative drugs
.
From 2018 to the first half of 2021, the R&D expenses of Rudizhe Medicine were 210 million yuan, 421 million yuan, 439 million yuan, and 258 million yuan respectively, "The increasing R&D expenses are the key factor for it to continuously launch innovative drugs ” said the relevant person
.
The company is currently in an important R&D investment period .
From 2018 to the first half of 2021, Shouyao Holding’s R&D investment was 31.
8365 million yuan, 43.
9103 million yuan, 85.
0327 million yuan and 65.
6151 million yuan respectively, and its research and development investment is also increasing .
It is reported that the company has formed a full-chain drug independent research and development platform, and has core technologies in key links such as target analysis and verification of small molecule innovative drug research and development, computer-aided drug design, lead compound optimization, and comprehensive drug screening and evaluation .
In addition, the alternately interspersed and multi-line parallel R&D model is used to replace the traditional single-line cycle research path, which greatly shortens the R&D cycle and improves the success rate of drug screening .
In order to break the vicious circle that Chinese biopharmaceutical companies are easily affected by the lack of product market space and the risk of a single product, Rongchang Bio has continued to invest in large-scale research and development .
The data shows that from 2018 to 2020, the compound annual growth rate of its R&D investment was 46.
70% .
At the same time, it has established a new drug R&D registration team of more than 1,000 people, independently developed technology platforms such as antibody fusion protein, ADC, and double antibody, and has a strong ability to export new drug projects continuously .
According to the industry, the pharmaceutical and biological industry has undergone many reshuffles, and the development of the innovative drug field has experienced growth from scratch.
It has now entered a golden period of development.
In the future, innovative drug companies with outstanding R&D capabilities and high production efficiency are expected to stand out
.
"Testing and Calibration of Dry Body Temperature Calibrators" is about to be broadcast, welcome to sign up Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to anyone
.
.
In recent years, with the country's continuous emphasis on innovative drugs, pharmaceutical companies have begun to increase investment in research and development to achieve transformation
.
Among them, the old brand Yunnan Baiyao has also begun to firmly transform itself in the throes.
The data shows that in 2021, the R&D expenses of Yunnan Baiyao will increase by 82.
99% year-on-year, and 7 national scientific research platforms have been established
.
Yunnan Baiyao said that the competition of modern biomedical technology enterprises is essentially the competition of talents and innovation ability
.
In the future, Yunnan Baiyao will be based on an excellent talent team, driven by continuous innovation investment, and rely on strong independent research and development capabilities and global resource integration capabilities to integrate various product forms to create comprehensive pharmaceutical solutions
.
It is also worth noting that as of the close of April 8, 1,220 of the 2021 annual results disclosed by 1,369 A-share listed companies disclosed research and development expenses, totaling 519.
893 billion yuan, a year-on-year increase of 20.
26%
.
Among them, according to the sorting out, most of the companies with R&D expenses accounting for a large proportion of operating income belong to the technological innovation industry, involving fields such as computers, medicine and biology
.
For example, in terms of the proportion of R&D expenses, three pharmaceutical companies, including Dizhe Pharmaceuticals, Shouyao Holding, and Shanghai Yizhong, will account for more than 320% of their operating income in 2021
.
In addition, the R&D expenditures of 36 companies including Junshi Bio, Rongchang Bio, Sunshine Guojian, and Microchip Bio also accounted for more than 20% of their operating income
.
Among them, Junshi Bio’s R&D investment in 2021 will increase by 15.
07% year-on-year to 2.
069 billion yuan, accounting for more than 50% of the total revenue; the number of R&D personnel has increased from 667 to 896, of which R&D personnel with doctoral and master’s degrees have reached 420 people
.
It is understood that in recent years, many pharmaceutical companies have continuously expanded their R&D investment to promote the development of innovative drugs
.
From 2018 to the first half of 2021, the R&D expenses of Rudizhe Medicine were 210 million yuan, 421 million yuan, 439 million yuan, and 258 million yuan respectively, "The increasing R&D expenses are the key factor for it to continuously launch innovative drugs ” said the relevant person
.
The company is currently in an important R&D investment period .
From 2018 to the first half of 2021, Shouyao Holding’s R&D investment was 31.
8365 million yuan, 43.
9103 million yuan, 85.
0327 million yuan and 65.
6151 million yuan respectively, and its research and development investment is also increasing .
It is reported that the company has formed a full-chain drug independent research and development platform, and has core technologies in key links such as target analysis and verification of small molecule innovative drug research and development, computer-aided drug design, lead compound optimization, and comprehensive drug screening and evaluation .
In addition, the alternately interspersed and multi-line parallel R&D model is used to replace the traditional single-line cycle research path, which greatly shortens the R&D cycle and improves the success rate of drug screening .
In order to break the vicious circle that Chinese biopharmaceutical companies are easily affected by the lack of product market space and the risk of a single product, Rongchang Bio has continued to invest in large-scale research and development .
The data shows that from 2018 to 2020, the compound annual growth rate of its R&D investment was 46.
70% .
At the same time, it has established a new drug R&D registration team of more than 1,000 people, independently developed technology platforms such as antibody fusion protein, ADC, and double antibody, and has a strong ability to export new drug projects continuously .
According to the industry, the pharmaceutical and biological industry has undergone many reshuffles, and the development of the innovative drug field has experienced growth from scratch.
It has now entered a golden period of development.
In the future, innovative drug companies with outstanding R&D capabilities and high production efficiency are expected to stand out
.
"Testing and Calibration of Dry Body Temperature Calibrators" is about to be broadcast, welcome to sign up Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to anyone
.
